Viagra vs Alprostadil (Caverject/MUSE): Real-World Evidence Comparison

How Each Drug Works

Sildenafil and alprostadil both produce erections, but they act through entirely different biological pathways. Sildenafil blocks phosphodiesterase type 5 (PDE5), preventing the breakdown of cyclic GMP and thereby sustaining smooth-muscle relaxation in the corpus cavernosum, but only when sexual arousal is already present. Alprostadil is a synthetic prostaglandin E1 (PGE1) that directly stimulates adenylate cyclase, raises intracellular cyclic AMP, and causes smooth-muscle relaxation independent of arousal or intact nitric oxide signaling.

Sildenafil Mechanism

Because sildenafil depends on endogenous nitric oxide release, men with severely impaired NO signaling (advanced diabetes, radical prostatectomy, severe arterial disease) may get a blunted response. The drug has no direct vasoactive effect on its own. Onset is 30 to 60 minutes after oral dosing, and the therapeutic window extends to roughly 4 to 6 hours [1].

Alprostadil Mechanism

Alprostadil bypasses the NO pathway entirely. The intracavernosal route (Caverject) deposits drug directly into erectile tissue, producing an erection within 5 to 20 minutes that is largely dose-dependent. The intraurethral suppository (MUSE) relies on absorption through the urethral mucosa into the corpus spongiosum and then diffusion into the corpora cavernosa, a less efficient path that explains its lower at-home success rate compared to injection [2].

Key Trial Efficacy

Sildenafil: The Goldstein 1998 NEJM Trial

The landmark sildenafil dose-escalation trial by Goldstein et al., published in the New England Journal of Medicine in 1998, enrolled 532 men with erectile dysfunction of organic, psychogenic, or mixed etiology [1]. At the maximum studied dose of 100 mg, 69% of men reported improved erections versus 22% in the placebo arm (P<0.001). The International Index of Erectile Function (IIEF) erectile function domain score rose by a mean of 7.0 points on sildenafil versus 1.9 points on placebo.

Subgroup data from that trial showed response rates varied meaningfully by etiology: men with psychogenic ED responded at roughly 84%, while men with diabetes responded at approximately 56%, a difference that foreshadowed the later evidence supporting alprostadil in metabolic comorbidity populations.

Alprostadil Injection: The Linet 1996 NEJM Trial

Linet and Ogrinc published the key Caverject trial in the New England Journal of Medicine in 1996, reporting outcomes in 683 men across a 6-month home-use period [2]. At optimized doses (titrated from 2.5 mcg to 20 mcg), 94.8% of injection attempts resulted in erections sufficient for intercourse. Patient satisfaction scores exceeded 87%. Penile pain occurred in 50% of participants but was rated mild in most, and priapism (erection lasting >4 hours) occurred in 1.3% of men during dose titration.

MUSE Intraurethral Alprostadil

MUSE (Medicated Urethral System for Erection) uses a small pellet of alprostadil inserted into the urethra. In-office testing success rates average 70%, but home-use data from a randomized trial of 1,511 men showed 64.9% of men who responded in-office were able to have intercourse at home, translating to an overall at-home success rate closer to 40 to 50% [3]. Urethral burning affects approximately 36% of users, and hypotension occurs in about 3%.

Real-World Evidence and Comparative Effectiveness

Head-to-head randomized trials comparing sildenafil directly to alprostadil injection are limited in number, but real-world registry and cohort data provide useful benchmarks.

PDE5 Inhibitor Failure and Alprostadil Rescue

A 2001 study published in the Journal of Urology followed 245 men who had failed sildenafil at 100 mg and were subsequently started on intracavernosal alprostadil [4]. Of those men, 89% achieved erections sufficient for intercourse with alprostadil monotherapy, confirming that PDE5 inhibitor failure does not predict alprostadil failure. The two mechanisms are genuinely complementary. A man who cannot generate adequate cyclic GMP through the NO pathway may have entirely intact adenylate cyclase responsiveness.

Diabetic Men

Diabetes reduces both NO bioavailability and autonomic nerve function, creating a dual handicap for PDE5 inhibitors. A Cochrane systematic review examining PDE5 inhibitor efficacy in type 2 diabetic men found a pooled response rate of approximately 50 to 60%, substantially below the 70% seen in mixed-etiology populations [5]. By contrast, alprostadil injection studies in diabetic men have consistently shown response rates of 80 to 90%, making it the preferred rescue agent in this subgroup.

Post-Prostatectomy

Radical prostatectomy severs the cavernous nerves. Sildenafil may produce modest benefit in nerve-sparing procedures, but its dependency on intact NO signaling limits efficacy in non-nerve-sparing cases. A prospective cohort study of 91 post-prostatectomy men found that intracavernosal alprostadil produced erections adequate for intercourse in 73% of non-nerve-sparing and 88% of nerve-sparing patients [6]. These figures far exceed the sildenafil response rates in the same surgical context.

Long-Term Dropout

Real-world persistence data reveal a clinically significant problem with alprostadil injection: dropout. A Swedish registry study tracking 1,286 men on intracavernosal therapy found that only 46% were still using therapy at 12 months, with needle phobia and partner reluctance as the most commonly cited reasons [7]. Sildenafil 12-month persistence in a U.S. Pharmacy claims database was significantly higher at approximately 65%, driven by the convenience of an oral tablet [8].

Dosing and Administration

Sildenafil Dosing

The FDA-approved dosing range for sildenafil is 25 mg, 50 mg, and 100 mg taken orally approximately 60 minutes before sexual activity, no more than once daily [9]. A high-fat meal delays absorption by up to 60 minutes and reduces peak plasma concentration (Cmax) by approximately 29%. Clinicians generally start at 50 mg and titrate based on response and tolerability.

Caverject Dosing

Intracavernosal alprostadil (Caverject) is started at 2.5 mcg in the clinic and titrated in 2.5 to 5 mcg increments until the lowest dose producing an erection lasting 30 to 60 minutes is identified [2]. The maximum recommended single dose is 40 mcg. Injections are limited to three times per week with at least 24 hours between uses. Patients require in-office training on self-injection technique before home use.

MUSE Dosing

MUSE suppositories are available in 125 mcg, 250 mcg, 500 mcg, and 1,000 mcg strengths. The recommended starting dose is 125 to 250 mcg, with an in-office test dose before home use. Patients are advised to urinate before insertion (to lubricate the urethra), insert the suppository, and stand or sit for 10 minutes while gently rolling the penis between the palms to improve distribution [3].

Safety and Side Effects

Sildenafil Safety Profile

Sildenafil's most clinically significant risk is profound hypotension when combined with any organic nitrate (nitroglycerin, isosorbide mononitrate). This combination is absolutely contraindicated [9]. Common adverse effects include headache (16%), flushing (11%), dyspepsia (7%), and transient blue-tinted vision from PDE6 cross-inhibition at higher doses. Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported in post-marketing data, though causality has not been confirmed.

Alprostadil Safety Profile

Penile pain is the most frequent adverse effect of alprostadil in both delivery forms. In the Linet 1996 trial, 50% of Caverject users reported pain at some point during 6 months of use, though only 11% rated it as moderate or severe [2]. Priapism requiring treatment occurs in approximately 1% of injection attempts and represents a urologic emergency requiring prompt aspiration and phenylephrine injection. Penile fibrosis from repeated injection trauma affects roughly 2 to 8% of long-term users. Systemic hypotension is more common with MUSE (3% of users) than with Caverject because urethral absorption allows more drug to enter the systemic circulation.

Patient Selection and Switching Criteria

Most men with erectile dysfunction receive a PDE5 inhibitor first. Several clinical scenarios warrant either initial selection of alprostadil or a switch from sildenafil.

When to Start with Alprostadil

• Concurrent nitrate use makes sildenafil absolutely contraindicated.
• Severe arterial insufficiency (pudendal artery occlusion, Leriche syndrome) typically produces a poor sildenafil response even at 100 mg.
• Non-nerve-sparing radical prostatectomy removes the cavernous nerves that PDE5 inhibitors depend on.
• Patient preference for erection independent of arousal (alprostadil does not require sexual stimulation).

When to Switch from Sildenafil to Alprostadil

The American Urological Association (AUA) guideline on ED management states: "Vacuum erection devices and intracavernosal vasoactive drug injection are recommended as second-line therapies in patients who fail or are intolerant of oral PDE5 inhibitors." [10] A switch to Caverject is appropriate after two consecutive failures at the maximum tolerated sildenafil dose, assuming adequate sexual stimulation was present and the drug was taken correctly (on an empty stomach or light meal, 60 minutes before activity).

Clinicians should verify compliance before declaring PDE5 inhibitor failure. A 2019 analysis of 4,200 men presenting with reported sildenafil failure found that 38% had never taken the drug correctly (eaten a high-fat meal, insufficient time before activity, or inadequate stimulation) [11]. Correcting administration errors resolved the problem in approximately half of those men.

Combination Therapy

Some men with partial sildenafil response benefit from adding low-dose alprostadil rather than completely switching. A randomized trial of 40 men with diabetes and partial PDE5 inhibitor response found that adding 5 to 10 mcg intracavernosal alprostadil to their usual sildenafil dose produced successful intercourse in 82% versus 44% with sildenafil alone (P<0.001) [12]. Combination use is off-label but clinically practiced in men with refractory ED at academic centers.

Cost and Access

Sildenafil became generic in the United States in 2017. Generic sildenafil 100 mg tablets are available for as low as $1.50, $4.00 per tablet through major pharmacy discount programs, making oral therapy by far the more affordable first-line option. Brand-name Viagra retains a list price above $60 per tablet.

Caverject Impulse 20 mcg cartridges have a retail price of approximately $100, $200 for a pack of six, with generic alprostadil injection formulations offering modest savings. MUSE suppositories cost roughly $60, $150 per suppository at retail, making frequent use expensive. Most insurance plans cover generic sildenafil; coverage for alprostadil is inconsistent and often requires prior authorization following documented PDE5 inhibitor failure [9].

Practical Administration Comparison

| Feature | Sildenafil (Viagra) | Caverject (injection) | MUSE (suppository) | |---|---|---|---| | Route | Oral | Intracavernosal injection | Intraurethral | | Onset | 30 to 60 min | 5 to 20 min | 10 to 30 min | | Duration | 4 to 6 hours | 30 to 60 min (dose-dependent) | 30 to 60 min | | Requires arousal | Yes | No | No | | Key trial success | ~70% | ~95% per attempt | ~65% in-office | | Priapism risk | Very low | ~1% | <1% | | Penile pain | Rare | Up to 50% | ~36% | | Nitrate contraindication | Absolute | None | None | | Typical cost (generic) | $2 to 4/dose | $15 to 35/dose | $60 to 150/dose |

Guidelines Summary

The AUA 2018 erectile dysfunction guideline (updated 2024) places oral PDE5 inhibitors as first-line therapy for most men with ED, with intracavernosal alprostadil as the preferred second-line agent after PDE5 inhibitor failure or contraindication [10]. The European Association of Urology (EAU) 2024 guidelines align with this hierarchy, additionally noting that penile rehabilitation programs after radical prostatectomy may use alprostadil injection daily at low doses (2.5 to 5 mcg) to preserve oxygenation of erectile tissue during nerve recovery, a use that sildenafil cannot replicate because arousal-independent delivery is required [13].